Companies › Nexcella
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NXC-201 CAR-T anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Light Chain (AL) Amyloidosis | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06097832 | NXC-201 CAR-T | Phase 1 | Light Chain (AL) Amyloidosis | Metabolic and endocrine | Dec 2026 |
iCell Gene Therapeutics AbbVie Chongqing Precision Biotech Poseida Therapeutics Regeneron Pharmaceuticals Johnson & Johnson (Janssen) AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.